Mode
Text Size
Log in / Sign up
N/A N=326,658

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

Intrauterine Devices

Enrolled (actual)
326,658
Serious AEs
Results posted
Dec 2020
Primary outcome: Primary: Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions — 4.25; 2.50 per 1000 person-years

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Intrauterine device (Device)
Age
Pediatric, Adult
Sex
Female
Sponsor
Bayer
Primary completion
Nov 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Crude Incidence Rate of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
4.25; 2.50
PRIMARY
Cumulative Incidence of Uterine Perforation Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
0.60; 0.35; 1.61; 0.88
PRIMARY
Adjusted Hazard Ratio (HR) for Breastfeeding Status and Uterine Perforation-first Observed IUD Insertions
1.37
PRIMARY
Crude Incidence Rate of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions
5.14; 3.77; 2.24; 0.68
PRIMARY
Cumulative Incidence of Uterine Perforation Categorized by Postpartum Timing-first Observed IUD Insertions
0.70; 0.54; 0.33; 0.07; 1.89; 1.42
PRIMARY
Adjusted Hazard Ratio (HR) for Postpartum Timing and Uterine Perforation-first Observed IUD Insertions
6.29; 4.65; 2.94
PRIMARY
Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and Uterine Perforation-first Observed IUD Insertions
3.44
PRIMARY
Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and Uterine Perforation-first Observed IUD Insertions
4.36
PRIMARY
Adjusted Incidence Rate Ratio (IRR) for Uterine Perforation-first Observed IUD Insertions
4.72; 4.10; 1.11; 6.61; 1.47; 4.86
PRIMARY
Adjusted Incidence Rate Difference (IRD) for Uterine Perforation-first Observed IUD Insertions
3.75; 2.28; 0.63; 3.92; 1.38; 2.33
PRIMARY
Crude Incidence Rate of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions
1.64; 1.27
PRIMARY
Cumulative Incidence of Uterine Perforation Stratified by IUD Type-first Observed IUD Insertions
0.22; 0.16; 0.63; 0.55
PRIMARY
Adjusted Hazard Ratio (HR) for IUD Type and Uterine Perforation-first Observed IUD Insertions
1.49
PRIMARY
Crude Incidence Rate of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions
1.00; 1.63
PRIMARY
Cumulative Incidence of Uterine Perforation Stratified by Menorrhagia Status-first Observed IUD Insertions
0.10; 0.22; 0.41; 0.63
PRIMARY
Adjusted Hazard Ratio (HR) for Menorrhagia Status and Uterine Perforation-first Observed IUD Insertions
1.38
PRIMARY
Effect Modification of Breastfeeding Status on Postpartum Timing for Uterine Perforation
1.28; 2.41; 1.36; 2.56
PRIMARY
Effect Modification of IUD Type on Breastfeeding Status for Uterine Perforation
1.33; 1.66
PRIMARY
Effect Modification of IUD Type on Postpartum Timing for Uterine Perforation
6.78; 5.11; 3.13; 4.30; 2.61; 2.01
SECONDARY
Crude Incidence Rate of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
10.23; 14.58
SECONDARY
Cumulative Incidence of IUD Expulsion Stratified by Breastfeeding Status Among Women Within 52 Weeks Postpartum-first Observed IUD Insertions
1.55; 2.45; 3.49; 4.57
SECONDARY
Adjusted Hazard Ratio (HR) for Breastfeeding Status and IUD Expulsion-first Observed IUD Insertions
0.71
SECONDARY
Crude Incidence Rate of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions
46.54; 10.88; 15.33; 9.29; 14.36; 14.93
SECONDARY
Cumulative Incidence of IUD Expulsion Categorized by Postpartum Timing-first Observed IUD Insertions
7.84; 3.87; 2.46; 1.40; 2.33; 2.49
SECONDARY
Adjusted Hazard Ratio (HR) for Postpartum Timing and IUD Expulsion-first Observed IUD Insertions
1.93; 0.88; 1.38; 1.32; 1.03; 1.39
SECONDARY
Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 14-week Cut Point and IUD Expulsion-first Observed IUD Insertions
0.88
SECONDARY
Adjusted Hazard Ratio (HR) for Postpartum Timing Risk 36-week Cut Point and IUD Expulsion-first Observed IUD Insertions
0.95
SECONDARY
Adjusted Incidence Rate Ratio (IRR) for IUD Expulsion-first Observed IUD Insertions
1.21; 1.20; 0.60; 1.25; 0.80; 1.23
SECONDARY
Adjusted Incidence Rate Difference (IRD) for IUD Expulsion-first Observed IUD Insertions
4.28; 2.37; -10.79; -2.62; 5.11; 2.65
SECONDARY
Crude Incidence Rate of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions
13.95; 14.08
SECONDARY
Cumulative Incidence of IUD Expulsion Stratified by IUD Type-first Observed IUD Insertions
2.30; 2.30; 4.52; 4.82
SECONDARY
Adjusted Hazard Ratio (HR) for IUD Type and IUD Expulsion-first Observed IUD Insertions
0.69
SECONDARY
Crude Incidence Rate of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions
39.56; 11.10
SECONDARY
Cumulative Incidence of IUD Expulsion Stratified by Menorrhagia Status-first Observed IUD Insertions
6.89; 1.78; 11.89; 3.72
SECONDARY
Adjusted Hazard Ratio (HR) for Menorrhagia Status and IUD Expulsion-first Observed IUD Insertions
2.79
SECONDARY
Effect Modification of IUD Type on Breastfeeding Status for IUD Expulsion
0.72; 0.66
SECONDARY
Effect Modification of IUD Type on Postpartum Timing for IUD Expulsion
1.59; 1.01; 1.40; 1.23; 0.96; 1.35
SECONDARY
Number of Indicators of a Potentially Difficult Insertion, Overall, by Breastfeeding Status, and by Postpartum Timing of IUD Insertion-first Observed IUD Insertions
29777; 1686; 1077; 573; 1261; 1146
SECONDARY
Number of Indicators of a Potentially Difficult Insertion, Overall, by IUD Type and by Menorrhagia Status-first Observed IUD Insertions
29777; 24666; 4648; 3754; 26023

Summary

Study to analyze electronic medical records of women using an intrauterine device (IUD). The study was required by the FDA for the marketed IUD Mirena (US Post-marketing requirement; short name of study: APEX IUD). The study analyzed the risks that the IUD was expelled or perforated the womb for the following group comparisons: * Women who were breastfeeding at the time of IUD insertion and within 52 weeks postpartum versus women who were not breastfeeding at the time of IUD insertion and within 52 weeks postpartum. * Women who had a first observed IUD insertion within different time periods after childbirth (i.e., ≤ 6 weeks, > 6 weeks and ≤ 14 weeks, > 14 weeks and ≤ 52 weeks) versus women who had their first observed IUD insertion more than 52 weeks after childbirth, including women without a recorded delivery within the past 52 weeks. An additional analysis involved 5-level postpartum timing (i.e., 0 to 3 days, 4 days to ≤ 6 weeks, > 6 weeks to ≤ 14 weeks, > 14 weeks to ≤ 52 weeks) versus the > 52 week postpartum group. The study also analyzed the risks that the IUD was expelled or perforated the womb for different types of IUDs. In addition, the study aimed to assess the following interactions: * The extent to which the type of IUD (IUDs releasing the hormone LNG versus Copper IUDs) modified the risk that an IUD was expelled or perforated the womb in relation to breastfeeding and/ or in relation to the point in time when the IUD was inserted after childbirth. * The extent to which the breastfeeding status modified the risk that an IUD was expelled or perforated the womb in relation to the point in time when the IUD was inserted after childbirth.

Eligibility Criteria

Inclusion Criteria

  • Women with evidence in the database of insertion of an IUD (e.g. levonorgestrel-releasing, copper) during the study time window for each site
  • Enrolled in the database with electronic medical records available for review for at least 12 months before the IUD insertion

Exclusion Criteria

  • Women with more than 50 years of age at the time of the IUD-insertion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03754556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search